Risk factors

Eastern Co's risk profile is dominated by supply chain vulnerabilities, labor union expirations, and debt covenant restrictions with $42.2 million in consolidated indebtedness.

High geographic concentration in Illinois and Mississippi drives revenue, exposing the company to regional disruptions and heavy debt obligations.

First Watch operates breakfast and brunch restaurants facing concentrated regional risk in the southeast United States and Florida. Profitability depends heavily on commodity costs like pork, eggs, and avocados, plus labor wages. The company relies on a single broad-line distributor and faces extensive regulatory oversight.

Fox Paine entities control 83.8 percent of voting power, creating significant shareholder concentration risks. Business depends heavily on wholesale general agents distributing Penn-America products. Extensive insurance regulations and AM Best rating status heavily impact operations and dividends.

Groupon faces restructuring, material internal control weaknesses, and heavy reliance on mobile platforms, SEO, and cloud infrastructure.

This biopharmaceutical company faces substantial clinical development and financial risks typical of an early-stage enterprise without approved products or commercial revenue. The company relies heavily on its unproven PREDATOR platform and lead INDUKINE candidates, WTX-124 and WTX-330, to generate future value. Operations depend significantly on third-party contract manufacturing, patent protection, and ongoing capital raises while carrying a term loan facility.

InfuSystem's risks are dominated by healthcare reimbursement dependencies, regulatory compliance like Medicare supplier standards, and third-party supply chain vulnerabilities.

Company relies heavily on third-party licenses for prestige fragrance brands like Off-White, Lanvin, and Rochas. Operations face heavy international exposure, foreign currency swings, and global supply chain dependencies. Growth depends on executive leadership, acquisition financing, and navigating shifting trade and tariff policies.

LifeMD faces ongoing net losses of $18.7 million in 2024 and relies heavily on subscription-based prescription products.

Lyell is a clinical-stage biopharmaceutical company focused on T-cell therapies and the recently acquired IMPT-314 candidate. The company has incurred substantial net losses, has no approved products, and depends heavily on additional capital. Operations face risks from complex manufacturing processes, clinical trial execution, regulatory approvals, and intellectual property protection.

Oil and gas sector dependency dominates revenues, accounting for 57 percent in 2024. International operations in Canada, Europe, and Brazil generate 31 percent of revenues. Project Phoenix operational transformation aims to improve margins and reduce costs.

MaxCyte faces heavy risks from reliance on biotech customers, customer clinical setbacks, and manufacturing scale-up challenges for its ExPERT platform.